List of Excipients in Branded Drug ELESTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	BENZALKONIUM CHLORIDE
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	EDETATE DISODIUM
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	HYDROCHLORIC ACID
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	SODIUM CHLORIDE
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	SODIUM HYDROXIDE
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	SODIUM PHOSPHATE, MONOBASIC
Allergan Inc	ELESTAT	epinastine hydrochloride	0023-9201	WATER

Last updated: August 9, 2026

Epinastine hydrochloride ophthalmic solution 0.05%, marketed in the U.S. as ELESTAT, is a mature antihistamine and mast-cell stabilizer with limited active-ingredient differentiation. The strongest commercial opportunities are excipient and delivery-system upgrades: preservative-free multidose packaging, reduced ocular-surface irritation, improved retention, and differentiated combination or allergy-care products. The opportunity is primarily lifecycle management and platform commercialization rather than exclusivity on epinastine itself.

ELESTAT Excipient Strategy and Commercial Opportunities

What is ELESTAT and which excipients does it contain?

ELESTAT is an ophthalmic solution containing epinastine hydrochloride 0.05%, equivalent to 0.05% epinastine, for the temporary prevention of itching associated with allergic conjunctivitis. The U.S. product was approved by the FDA under NDA 21-565. Its formulation is an aqueous, preserved ophthalmic solution. [1]

The U.S. prescribing information identifies the inactive ingredients as:

Component	Formulation role
Benzalkonium chloride 0.01%	Antimicrobial preservative
Sodium phosphate, dibasic	Buffering and pH control
Sodium phosphate, monobasic	Buffering and pH control
Sodium chloride	Tonicity adjustment
Edetate disodium	Chelating agent and preservative-support excipient
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

The reference formulation uses a conventional preserved multidose ophthalmic platform. This architecture is low-cost and manufacturable, but benzalkonium chloride creates a clear lifecycle-management target because chronic or frequent exposure can aggravate ocular-surface irritation in susceptible patients.

What is the active pharmaceutical ingredient in ELESTAT?

The active ingredient is epinastine hydrochloride, a topical ophthalmic H1-antihistamine with mast-cell-stabilizing activity. Epinastine is administered locally to the eye, limiting the need for systemic exposure and making formulation tolerability, drop size, sterility, pH, osmolality, and preservative selection commercially important.

What excipient strategy is most attractive for epinastine ophthalmic products?

The highest-value strategy is to preserve the 0.05% epinastine concentration while changing the delivery platform. A reformulated product can pursue clinical and commercial differentiation without requiring a new active compound.

1. Preservative-free multidose delivery

A preservative-free version is the most credible premium opportunity. Conventional benzalkonium chloride preservation can be replaced by:

• A one-way valve multidose bottle
• An airless ophthalmic container
• A sterile-unit-dose presentation
• A filter-based or microbiologically protective dispensing system
• A compatible low-preservative or alternative-preservative system

The key commercial benefit is improved suitability for patients with dry eye, contact-lens intolerance, blepharitis, ocular-surface disease, or frequent seasonal dosing.

A preservative-free formulation creates several patentable elements:

• Container-closure architecture
• Valve and anti-backflow design
• Drop-size control
• Sterility-maintenance performance
• Extractables and leachables profile
• Formulation compatibility with the dispensing device
• In-use microbiological stability
• Manufacturing and filling process

The formulation alone may be difficult to protect if it consists of epinastine, conventional phosphate buffer, sodium chloride, and water without a distinctive technical feature. Device-formulation combinations generally offer stronger protection than routine excipient substitution.

2. Reduced-irritation preserved formulations

A lower-cost alternative is a reformulated preserved product using an excipient system with a more favorable ocular-surface profile. Potential approaches include:

• Lower benzalkonium chloride concentration
• Polyquaternium-1
• Stabilized oxychloro complex
• Peroxide-based systems, where compatible with the dosage form
• Other ophthalmically accepted antimicrobial systems

Each option requires compatibility testing with epinastine hydrochloride, container materials, buffer species, and manufacturing conditions. Preservative substitution is not automatically commercially superior. The product must maintain sterility throughout the labeled in-use period and demonstrate acceptable drop comfort, microbial preservation, and chemical stability.

The most defensible claim would be based on a defined technical result, such as preservation at a lower total preservative burden while maintaining potency and sterility. Broad claims covering any preservative-free epinastine solution would face enablement and obviousness pressure.

3. Buffer and pH optimization

The reference product uses a phosphate-buffered system. A new product could evaluate:

• Citrate buffer
• Borate buffer
• Histidine buffer
• Low-capacity buffer systems
• Reduced phosphate concentration
• pH optimization for comfort and chemical stability

A buffer change has value only if it solves a measurable problem. Potential advantages include:

• Improved epinastine stability
• Lower precipitation risk
• Better comfort on administration
• Reduced interaction with the container
• Improved compatibility with preservatives
• Better stability under temperature excursions

A strong formulation program would map epinastine degradation against pH, buffer concentration, ionic strength, oxygen exposure, light, and storage temperature. The commercial objective is a formulation with a defensible stability or tolerability advantage, not a routine excipient swap.

4. Chelator optimization

Edetate disodium can support preservative performance by binding trace metal ions that promote degradation or microbial survival. A reformulation could study:

• Lower edetate concentration
• Alternative chelators
• Chelator-free systems
• Chelator combinations with alternative preservatives

Chelator changes may improve tolerability or regulatory positioning, but the patent value is usually modest unless the change produces an unexpected stability, preservation, or compatibility result.

5. Drop-size and residence-time engineering

Ophthalmic commercial differentiation can come from delivery performance rather than composition. A smaller drop can reduce overflow, improve dosing efficiency, and lower systemic drainage. A formulation or device that produces a controlled drop size may support:

• Lower drug wastage
• Improved patient acceptance
• More consistent dosing
• Reduced exposure to preservatives
• Better fit for pediatric or elderly users

Increasing ocular residence time is more difficult. Candidate approaches include viscosity modifiers, mucoadhesive polymers, in situ gelling systems, and surface-active excipients. These approaches introduce risks involving blurred vision, instillation comfort, filterability, sterilization, and dose uniformity.

A modest viscosity increase may be commercially preferable to a gel-forming product if it improves retention without affecting visual acuity immediately after dosing.

What formulations are protected by the ELESTAT product?

The original ELESTAT formulation is protected primarily through the approved drug product, regulatory controls, trademarks, manufacturing know-how, and any relevant historical patent rights. The label does not establish broad ownership of all epinastine ophthalmic formulations. [1]

The commercial formulation space can be divided into four categories:

Formulation category	Differentiation potential	Main barrier
Conventional preserved solution	Low	Generic substitution
Reduced-preservative solution	Moderate	Need for tolerability and preservation data
Preservative-free unit dose	Moderate	Higher packaging and manufacturing cost
Preservative-free multidose device	High	Device qualification, sterility, and regulatory complexity
Viscous or in situ gel	Moderate to high	Blurring, comfort, dose uniformity
Combination allergy product	High	Clinical development and regulatory requirements

The strongest patent claims would likely combine composition and function. Examples include an epinastine solution with a defined preservative concentration, a specific buffer and pH range, a defined viscosity window, or a container that maintains sterility without a conventional preservative.

When does ELESTAT lose exclusivity and what is the generic risk?

ELESTAT is a mature small-molecule ophthalmic product. Its original regulatory and patent exclusivity periods have expired, and generic epinastine hydrochloride ophthalmic solutions have entered the U.S. market. FDA-approved generic products are listed in the Orange Book under epinastine hydrochloride ophthalmic solution. [2]

The principal risk profile is therefore:

Risk	Assessment
Generic active-ingredient competition	High
Conventional formulation price erosion	High
Preservative-free product substitution	Moderate
Device-based differentiation	Lower, if technically and clinically differentiated
Biosimilar risk	Not applicable
Paragraph IV litigation risk	Low for the original product at this stage
OTC allergy-category substitution	Moderate to high

Paragraph IV risk is most relevant to currently listed patents that remain enforceable and materially affect approval. For a mature ELESTAT product, the commercial issue is less likely to be a new Paragraph IV challenge to the original branded product and more likely to be competition among approved generic epinastine products and reformulated branded or specialty products.

What is the FDA regulatory status of ELESTAT?

ELESTAT was approved as a prescription ophthalmic solution for allergic conjunctivitis. The product is a small-molecule drug, not a biologic, so biosimilar pathways do not apply. Generic competitors generally rely on the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements applicable to ophthalmic products. [1,3]

A reformulated epinastine product could follow different regulatory routes:

505(b)(2) reformulation

A preservative-free or device-enabled product may be eligible for a 505(b)(2) application if it relies in part on FDA findings for an approved epinastine product while introducing a new formulation, dosage form, delivery device, or route-related characteristic. The sponsor would need to establish the safety and effectiveness of the modified product and address any required clinical or comparative studies.

Abbreviated new drug application

A product that is pharmaceutically equivalent and therapeutically equivalent to the reference product may pursue an ANDA. This pathway is less suitable for a materially differentiated preservative-free multidose device if the formulation or delivery system does not meet the relevant equivalence requirements.

OTC pathway

An over-the-counter allergy product would require a separate regulatory strategy. The active ingredient and indication would need to fit an applicable FDA monograph or undergo an NDA pathway. Prescription-to-OTC conversion could expand volume but would require consumer labeling, self-selection, human-factors, and safety analysis.

How strong is the patent estate for an ELESTAT reformulation?

The patent strength of a new epinastine product depends on whether the invention solves a measurable technical problem.

Stronger patent positions

• Preservative-free multidose delivery that maintains sterility during labeled use
• Defined epinastine formulation with improved stability under accelerated conditions
• Device-formulation combination with controlled drop size
• Reduced-irritation formulation supported by comparative ocular-surface data
• Specific polymer system that improves residence time without clinically meaningful blurring
• Manufacturing process that reduces degradation or particulate formation

Weaker patent positions

• Routine substitution of sodium chloride or phosphate salts
• Broad claims to epinastine ophthalmic solutions
• Conventional pH ranges without unexpected performance
• Generic preservative replacement without comparative data
• Standard unit-dose packaging with no unusual technical configuration

Patent applications should include a broad genus, narrower composition claims, device claims, process claims, and data linking each claimed range to stability, preservation, comfort, or performance. Trade secrets may protect manufacturing parameters that are difficult to reverse engineer, while patents should cover the product architecture visible to competitors.

Which companies could challenge or commercialize ELESTAT alternatives?

The competitive field includes three groups:

1. Generic ophthalmic manufacturers selling epinastine or substitutable antihistamine products.
2. Branded ophthalmology companies with preservative-free or ocular-surface product platforms.
3. Contract development and manufacturing organizations with sterile ophthalmic filling and specialized container systems.

Competitive products include other topical antihistamines such as olopatadine, ketotifen, azelastine, and bepotastine. These products compete on dosing frequency, tolerability, onset, availability, physician familiarity, and price rather than on epinastine excipients alone.

Product class	Commercial advantage over conventional ELESTAT
Generic epinastine	Lower price
Olopatadine products	Strong brand recognition and broad allergy positioning
Ketotifen products	OTC access in the U.S.
Preservative-free antihistamine products	Ocular-surface tolerability
Combination antihistamine/mast-cell stabilizers	Broader clinical positioning
Device-enabled ophthalmic products	Dosing consistency and convenience

The most credible partner profile is a company with sterile ophthalmic manufacturing, device-development capability, and an established ophthalmology sales channel. A conventional generic manufacturer has cost advantages but may lack the commercial infrastructure to support a premium preservative-free product.

What licensing deals could support an ELESTAT excipient strategy?

A licensing or co-development transaction could involve four assets:

• A preservative-free multidose ophthalmic device
• A proprietary antimicrobial or preservation system
• A polymer-based residence-time platform
• A combination product using epinastine with another allergy or ocular-surface active

The deal structure would likely include an upfront payment, development milestones, regulatory milestones, and royalties on net sales. The most valuable package would combine issued or pending patents with demonstration batches, container-closure data, microbial challenge results, and comparative tolerability data.

A device license without formulation ownership may produce weak negotiating leverage because competitors can develop alternative containers. A formulation patent without a qualified sterile manufacturing process may face execution risk. The strongest transaction combines composition, device, process, and clinical-performance evidence.

What revenue exposure and commercial opportunities exist?

Revenue exposure for conventional ELESTAT is concentrated in price-sensitive prescription and generic channels. The original product does not offer a strong basis for premium pricing unless the sponsor adds one of the following:

• Preservative-free dosing
• Better ocular-surface tolerability
• Longer duration or lower dosing frequency
• Improved drop delivery
• OTC convenience
• Combination therapy
• Specialty positioning for chronic or high-frequency users

A reformulated product can target higher-value segments:

Segment	Product proposition
Dry-eye patients with seasonal allergy	Preservative-free epinastine
Contact-lens users	Low-irritation or preservative-free dosing
Pediatric patients	Unit-dose or controlled-drop delivery
Elderly patients	Large-label device and easier actuation
High-frequency users	Reduced preservative burden
Allergy clinics	Premium formulation with tolerability data
Retail allergy market	OTC-compatible consumer presentation

The economic model must account for sterile fill-finish costs, single-use packaging, device royalties, product waste, and lower unit volumes. Preservative-free multidose products can command a premium, but the premium must offset container and manufacturing costs while remaining competitive with branded olopatadine and OTC ketotifen.

What manufacturing and intellectual-property barriers affect ELESTAT opportunities?

The principal manufacturing barriers are:

• Sterile filtration or aseptic processing
• Preservative-free filling
• Container-closure integrity
• Microbial ingress control
• Extractables and leachables
• Low-particulate manufacturing
• Consistent drop volume
• Device compatibility
• In-use stability
• Scale-up of viscous or polymer-containing formulations

A preservative-free multidose product requires robust microbiological control. The dispensing system must prevent contamination throughout the use period, and the sponsor must demonstrate performance after repeated actuation and handling.

The main intellectual-property barriers are:

• Existing patents on preservative-free ophthalmic devices
• Broad patents covering antimicrobial dispensing systems
• Formulation patents for antihistamine solutions
• Polymer and viscosity platform patents
• Freedom-to-operate risks involving container components
• Patent term and regulatory exclusivity limitations

A freedom-to-operate review should cover U.S., European, Japanese, and major emerging-market filings. Geographic value will differ because prescription status, generic penetration, patent enforcement, and OTC access vary by jurisdiction.

How does ELESTAT compare with competing ophthalmic antihistamines?

Attribute	Epinastine	Olopatadine	Ketotifen	Bepotastine
Class	H1 antagonist and mast-cell stabilizer	H1 antagonist and mast-cell stabilizer	H1 antagonist and mast-cell stabilizer	H1 antagonist and mast-cell stabilizer
Common commercial positioning	Prescription allergy treatment	Branded and generic allergy treatment	Strong OTC presence in the U.S.	Prescription allergy treatment
Excipient opportunity	Preservative-free and device reformulation	Similar, with stronger incumbent competition	OTC convenience and low price	Specialty and tolerability positioning
Main commercial risk	Mature generic market	Established branded and generic competition	Retail substitution	Smaller market scale
Biosimilar risk	None	None	None	None

Epinastine has a credible reformulation opportunity because its active ingredient is established and its reference product uses a conventional preserved solution. The limitation is market size and generic pricing pressure. A new product must offer a visible benefit that physicians, pharmacists, or consumers can understand.

Key Takeaways

• ELESTAT contains epinastine hydrochloride 0.05% in a conventional benzalkonium chloride-preserved ophthalmic solution.
• The original active-ingredient exclusivity has expired, and generic competition is established.
• The strongest lifecycle strategy is a preservative-free multidose product supported by a proprietary dispensing system.
• Reduced-preservative formulations, controlled drop size, and improved ocular-surface tolerability are secondary opportunities.
• Routine excipient substitutions have weak patent prospects without unexpected stability, preservation, or comfort results.
• A 505(b)(2) pathway may be suitable for a materially differentiated formulation or delivery device.
• Biosimilar risk does not apply because epinastine is a small molecule.
• Commercial success depends on premium positioning, sterile manufacturing economics, device ownership, and differentiated clinical data.
• The most valuable licensing package would combine formulation patents, device rights, manufacturing know-how, and comparative tolerability evidence.

FAQs About ELESTAT Excipient and Commercial Strategy

Can benzalkonium chloride be removed from ELESTAT?

Yes. A preservative-free epinastine product could use unit-dose packaging or a multidose container designed to prevent microbial ingress. The reformulation would require new stability, sterility, in-use, container-closure, and regulatory data.

Is epinastine suitable for an in situ gel formulation?

Potentially. A gel-forming formulation could increase ocular residence time, but viscosity, blurred vision, comfort, drop uniformity, sterilization, and patient acceptance would determine commercial viability.

Could a preservative-free ELESTAT product receive new patent protection?

Yes, if the product includes a novel and non-obvious formulation, dispensing system, manufacturing process, or demonstrated technical performance. A generic preservative substitution would provide a weaker patent position.

Does ELESTAT have biosimilar competition?

No. Epinastine hydrochloride is a small-molecule drug. Competition proceeds through generic-drug pathways rather than biosimilar approval pathways.

Is an OTC version of epinastine commercially attractive?

An OTC strategy could expand consumer access, but it would require a separate FDA regulatory and commercial program. The product would compete directly with established OTC ketotifen and branded or generic olopatadine products.

References

1. U.S. Food and Drug Administration. (2003). ELESTAT (epinastine hydrochloride ophthalmic solution) prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2016). ANDAs for certain highly purified synthetic peptides that reference listed drugs of rDNA origin: Guidance for industry. FDA.